211 related articles for article (PubMed ID: 33278177)
1. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.
Shah S; Hill A
Curr Opin Infect Dis; 2021 Feb; 34(1):16-24. PubMed ID: 33278177
[TBL] [Abstract][Full Text] [Related]
2. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication.
Shah S; Hill A
Curr Opin HIV AIDS; 2021 Mar; 16(2):106-114. PubMed ID: 33625041
[TBL] [Abstract][Full Text] [Related]
3. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
4. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.
Lake JE; Trevillyan J
Curr Opin HIV AIDS; 2021 May; 16(3):148-151. PubMed ID: 33797433
[TBL] [Abstract][Full Text] [Related]
5. Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV.
Ann Intern Med; 2021 Jun; 174(6):I21. PubMed ID: 33721514
[No Abstract] [Full Text] [Related]
6. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
7. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
8. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
9. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.
Kousari AE; Wilson MP; Hawkins KL; Bandali MM; Henao-Martínez AF; Gardner EM; Erlandson KM
HIV Res Clin Pract; 2024 Dec; 25(1):2339576. PubMed ID: 38831550
[TBL] [Abstract][Full Text] [Related]
10. Weight gain and integrase inhibitors.
Eckard AR; McComsey GA
Curr Opin Infect Dis; 2020 Feb; 33(1):10-19. PubMed ID: 31789693
[TBL] [Abstract][Full Text] [Related]
11. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
Capeau J; Lagathu C; Béréziat V
Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Consequences of Antiretroviral Therapy.
Diggins CE; Russo SC; Lo J
Curr HIV/AIDS Rep; 2022 Apr; 19(2):141-153. PubMed ID: 35299263
[TBL] [Abstract][Full Text] [Related]
13. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Perna A; Carleo MA; Mascolo S; Guida A; Contieri M; Sellitto C; Hay E; De Blasiis P; Lucariello A; Guerra G; Baldi A; De Luca A; Maggi P; Esposito V
AIDS; 2023 Mar; 37(4):561-570. PubMed ID: 36504092
[TBL] [Abstract][Full Text] [Related]
14. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen.
Darnell J; Jain S; Sun X; Qin H; Reynolds T; Karris MY; Hill LA
Medicine (Baltimore); 2021 Aug; 100(34):e27047. PubMed ID: 34449491
[TBL] [Abstract][Full Text] [Related]
15. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Lahiri CD; Xu Y; Wang K; Alvarez JA; Sheth AN; O'Halloran J; Spence AB; Tien P; Gustafson DR; Milam J; Fischl MA; Konkle-Parker D; Adimora AA; Sharma A; Weber KM; Ofotokun I; Rubin LH
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):461-467. PubMed ID: 33231474
[TBL] [Abstract][Full Text] [Related]
16. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy in older people with HIV.
Richterman A; Sax PE
Curr Opin HIV AIDS; 2020 Mar; 15(2):118-125. PubMed ID: 31990705
[TBL] [Abstract][Full Text] [Related]
18. Weight gain in HIV-infected individuals using distinct antiretroviral drugs.
Buzón-Martín L
AIDS Rev; 2020; 22(3):158-167. PubMed ID: 33118531
[TBL] [Abstract][Full Text] [Related]
19. HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.
Capeau J; Lagathu C; Ngono Ayissi K; Fève B; Béréziat V
Ann Endocrinol (Paris); 2024 Jun; 85(3):255-258. PubMed ID: 38871510
[TBL] [Abstract][Full Text] [Related]
20. Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks.
Carr M; Richardson R; Tong W; Bloch M; Baker D; Hoy JF;
AIDS; 2020 Apr; 34(5):789-790. PubMed ID: 31895147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
